Intra-nasal fentanyl for breathlessness
Phase 2
Completed
- Conditions
- Breathlessness in palliative care patients who have terminal illness from a non-malignant diseaseRespiratory - Other respiratory disorders / diseasesCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12617001399381
- Lead Sponsor
- Medical Director, Dr Ian Gwynne Robson
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
The study population is composed of enrolled hospice patients with the following eligibility criteria:
Age, 18 and above
Primary diagnosis of non-malignant disease
Symptom of episodic dyspnoea on a daily basis at least once per day in the previous week
already on rescue opioid for episodic dypsnea
Exclusion Criteria
Diagnosis of malignancy
Non English speaking
Unable to give informed consent
confirmed or suspected pregnancy
history of current history of depression
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method change in Visual analogue dyspnea scale at 15 minutes after administration of the studied drug[At 15 minutes after drug administration]
- Secondary Outcome Measures
Name Time Method